Poland· PL-100391782
Rixathon
A medicinal product containing rituximabum, registered in Poland by Sandoz GmbH.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Rituximabum
- Manufacturer
- Sandoz GmbH
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421025038
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rituximabum in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
- United StatesRiabniAmgen, Inc
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/24566a36-6d49-42ba-8680-fdee423d9be9 GET /v1/drugs/24566a36-6d49-42ba-8680-fdee423d9be9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg/ml (100 mg)",
"packaging": "07613421025038 ¦ Rpz ¦ EU/1/17/1185 /001 ¦ 123741\n2 fiol. 10 ml\nRpz ¦ EU/1/17/1185/002 ¦ 126154\n3 fiol. 10 ml",
"substance": "Rituximabum 100 mg",
"common_name": "Rituximabum",
"pl_product_id": "100391782",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rituximabum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.